

Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib

Andrew H. Lipsky,^{1,5,*} Mohammed Z.H. Farooqui,^{1,*} Xin Tian,² Sabrina Martyr,¹ Ann M. Cullinane,³ Khanh Nghiem,³ Clare Sun,¹ Janet Valdez,¹ Carsten U. Niemann,¹ Sarah E. M. Herman,¹ Nakhle Saba,¹ Susan Soto,¹ Gerald Marti,¹ Gulbu Uzel,⁴ Steve M. Holland,⁴ Jay N. Lozier,³ and Adrian Wiestner¹

¹Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD; ²Office of Biostatistics Research, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD; ³Department of Laboratory Medicine, NIH Clinical Center, Bethesda, MD; ⁴Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; and ⁵Department of Internal Medicine, Montefiore Medical Center, Bronx, New York, NY, USA

*AHL and MZHF contributed equally to this work and are co-first authors.

©2015 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.126672

Manuscript received on March 5, 2015. Manuscript accepted on September 24, 2015.

Correspondence: wiestner@mail.nih.gov or lozierj@cc.nih.gov

Table S1: Bleeding and Bruising Events in Patients on Ibrutinib

Patient ID	Nature of Bleeding	Start Day	CTCAE Grade	Duration of Event (Days)	Confounding Medications
PCI A01	Bruising	97	1	30	
	Bruising	421	1	110	
PCI A04	Bruising	69	1	Ongoing	
PCI A05	Bruising	534	1	91	
PCI A06	Bruising	169	1	38	
PCI A07	Bruising	14	1	Ongoing	Fish Oil
	Bruising	79	1	Ongoing	
	Bruising	611	1	Ongoing	Aspirin
PCI A08	Epistaxis	697	1	14	Aspirin
PCI A09	Epistaxis	10	1	14	Ibuprofen
PCI A10	Bruising	115	1	53	Aspirin
PCI A11	Bruising	15	1	10	
PCI A16	Oral hemorrhage	1	1	3	Ibuprofen
PCI A18	Petechiae	27	1	Ongoing	
PCI A19	Bruising	1	1	Ongoing	
PCI A20	Bruising	111	1	Ongoing	
	Bruising	535	1	Ongoing	
PCI A21	Bruising	19	1	51	Naproxen
	Bruising	600	1	Ongoing	
PCI A23	Bruising	1	1	Ongoing	
PCI A25	Bruising	22	1	Ongoing	
	Subconjunctival Bleeding	26	1	28	
	Oral hemorrhage	48	1	Ongoing	
PCI A30	Bruising	152	1	Ongoing	
	Bruising	213	1	Ongoing	
PCI A31	Petechiae	108	1	Ongoing	
PCI A32	Epistaxis	113	2	6	
	Bruising	104	1	Ongoing	Celecoxib
	Epistaxis	328	1	1	
PCI A35	Bruising	77	1	Ongoing	Aspirin
PCI B07	Petechiae	771	1	Ongoing	Ibuprofen
PCI B09	Bruising	86	1	Ongoing	Aspirin
PCI B10	Epistaxis	694	1	Ongoing	Apixaban
PCI B13	Bruising	9	1	101	
	Petechiae	54	1	28	
	Subconjunctival Bleeding	512	2	30	
PCI B16	Bruising	26	1	29	
PCI B17	Bruising	14	1	15	

	Petechiae	3	1	77	
	Bruising	255	1	Ongoing	
PCI B19	Bruising	13	1	14	Naproxen
PCI B20	Petechiae	84	1	28	Fish Oil
PCI B22	Bruising	49	1	124	Fish oil
	Petechiae	112	1	61	
PCI B25	Bruising	9	1	Ongoing	
PCI B26	Bruising	27	1	27	Aspirin
	Petechiae	27	1	27	Fish Oil
PCI B27	Petechiae	6	1	11	
	Bruising	12	1	42	Fish Oil
	Bruising	615	1	Ongoing	
PCI B32	Bruising	85	1	28	
PCI B33	Petechiae	44	1	Ongoing	
PCI B35	Petechiae	15	1	14	Ibuprofen
	Petechiae	136	1	Ongoing	
PCI B36	Petechiae	55	1	86	
	Petechiae	260	1	Ongoing	
PCI B37	Bruising	8	1	78	Aspirin
	Epistaxis	351	1	1	
	Petechiae	351	1	Ongoing	
PCI B39	Subconjunctival	49	1	21	
	Bleeding				
	Bruising	141	1	35	
	Bruising	202	1	Ongoing	
	Bruising	358	1	Ongoing	
PCI B42	Bruising	140	1	Ongoing	
	Bruising	260	1	Ongoing	
PCI B44	Bruising	22	1	30	
	Petechiae	53	1	30	
PCI B45	Bruising	108	2	32	
PCI B47	Bruising	13	1	43	Aspirin
PCI B48	Bruising	5	1	Ongoing	
PCI B49	Bruising	121	1	Ongoing	Fish Oil
PCI B50	Epistaxis	8	2	4	Naproxen
	Epistaxis	53	1	1	Aspirin
PCI B51	Bruising	131	1	Ongoing	
PCI B52	Bruising	85	1	21	

Table S2. Univariate analysis of risk factors for bleeding or bruising

<i>Continuous variable</i>	N	Hazard Ratio (95% CI)	P
EPI Closure Time (min)	66	1.34 (1.02 – 1.75)	0.031
Factor VIII (IU/dl)	77	0.997 (0.994 – 1.001)	0.13
vWF Activity(IU/dl)	77	0.996 (0.991 – 1.001)	0.11
vWF Antigen (IU/dl)	77	0.997 (0.992– 1.001)	0.13
<i>Dichotomized variable</i>			
Epi Closure Time, ≥ 240 sec	66	2.70 (1.26 – 5.79)	0.008
Factor VIII, ≤ 174 IU/dl	77	2.89 (1.52 – 5.50)	0.0007
vWF Activity, ≤ 100 IU/dl	77	2.25 (1.13 – 4.48)	0.017
vWF Antigen, < 90 IU/dl	77	1.98 (0.92 – 4.31)	0.077

Supplemental Figure 1:

